Docetaxel albumin bound (Celgene Corp)

多西他赛（白蛋白结合型）（Celgene Corp）

Report date: 2025/07/14 20:01:16

Base Information

Drug NameDocetaxel albumin bound (Celgene Corp)
Drug Alias NameABI-008
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitorsTubulin inhibitors
TargetsTubulin
Therapy Area/IndicationsMetastatic breast cancerHormone-Resistant Prostate NeoplasmsSolid tumours +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
Inactive CompaniesCelgene Corp
Active IndicationsSolid tumoursStomach NeoplasmsEsophageal Neoplasms +[4] 
Inactive IndicationsMetastatic breast cancerHormone-Resistant Prostate Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A